ALKBH5‐mediated m6A demethylation ameliorates extracellular matrix deposition in cutaneous pathological fibrosis
Authors:
Open Access
- 4 September 2024
- journal article
- research article
- Published by Wiley in Clinical and Translational Medicine
- Vol. 14 (9) , e70016
Abstract
Background: Elevated extracellular matrix (ECM) accumulation is a major contributing factor to the pathogenesis of fibrotic diseases. Recent studies have indicated that N6‐methyladenosine (m6A) RNA modification plays a pivotal role in modulating RNA stability and contribute to the initiation of various pathological conditions. Howbeit, the precise mechanism by which m6A influences ECM deposition remains unclear.Methods: In this study, we used hypertrophic scars (HTSs) as a paradigm to investigate ECM‐related diseases. We focused on the role of ALKBH5‐mediated m6A demethylation within the pathological progression of HTSs and examined its correlation with clinical stages. The effects of ALKBH5 ablation on ECM components were studied both in vivo and in vitro. Downstream targets of ALKBH5, along with their underlying mechanisms, were identified using integrated high‐throughput analysis, RNA‐binding protein immunoprecipitation and RNA pull‐down assays. Furthermore, the therapeutic potential of exogenous ALKBH5 overexpression was evaluated in fibrotic scar models.Results: ALKBH5 was decreased in fibroblasts derived from HTS lesions and was negatively correlated with their clinical stages. Importantly, ablation of ALKBH5 promoted the expression of COL3A1, COL1A1, and ELN, leading to pathological deposition and reconstruction of the ECM both in vivo and in vitro. From a therapeutic perspective, the exogenous overexpression of ALKBH5 significantly inhibited abnormal collagen deposition in fibrotic scar models. As determined by integrated high‐throughput analysis, key ECM components including COL3A1, COL1A1, and ELN are direct downstream targets of ALKBH5. By means of its mechanism, ALKBH5 inhibits the expression of COL3A1, COL1A1, and ELN by removing m6A from mRNAs, thereby decreasing their stability in a YTHDF1‐dependent manner.Conclusions: Our study identified ALKBH5 as an endogenous suppressor of pathological ECM deposition, contributing to the development of a reprogrammed m6A‐targeted therapy for HTSs.Keywords
Funding Information
- National Natural Science Foundation of China (82072177, 82302805)
- China Postdoctoral Science Foundation (2022M722132, 2024M752023)
This publication has 28 references indexed in Scilit:
- Dipeptidyl Peptidase-4–Mediated Fibronectin Processing Evokes a Profibrotic Extracellular MatrixJournal of Investigative Dermatology, 2024
- ALKBH5 SUMOylation-mediated FBXW7 m6A modification regulates alveolar cells senescence during 1-nitropyrene-induced pulmonary fibrosisJournal of Hazardous Materials, 2024
- Extracellular matrix in skin diseases: The road to new therapiesJournal of Advanced Research, 2022
- Matrikines as mediators of tissue remodellingAdvanced Drug Delivery Reviews, 2022
- The proteasome-dependent degradation of ALKBH5 regulates ECM deposition in PM2.5 exposure-induced pulmonary fibrosis of miceJournal of Hazardous Materials, 2022
- The interplay of fibroblasts, the extracellular matrix, and inflammation in scar formationJournal of Biological Chemistry, 2021
- Emerging and innovative approaches for wound healing and skin regeneration: Current status and advancesBiomaterials, 2019
- Type III collagen affects dermal and vascular collagen fibrillogenesis and tissue integrity in a mutant Col3a1 transgenic mouse modelMatrix Biology, 2018
- N6-methyladenosine Modulates Messenger RNA Translation EfficiencyCell, 2015
- Comprehensive Analysis of mRNA Methylation Reveals Enrichment in 3′ UTRs and near Stop CodonsCell, 2012